Signaling through a complex of proteins called mTORC2 plays a role in breast cancer migration, invasion and metastasis, Vanderbilt researchers reported.

Carlos L. Arteaga, M.D., director of the Center for Cancer Targeted Therapies (C2T2), director of the Breast Cancer Research Program and associate director for Clinical Research at Vanderbilt-Ingram Cancer Center (VICC), has been named director of the Harold C. Simmons Comprehensive Cancer Center and associate dean of Oncology Programs at the UT Southwestern Medical Center in Dallas.

Bile acids produced by a western diet alter the composition of the gut microbiota and promote intestinal carcinogenesis.

Vanderbilt investigators have conducted a first-of-its-kind genome-wide association study of lung cancer survival in African-Americans.

A novel immunotherapy combination induced remarkable regression of tumors in a mouse model of head and neck cancer.

Los Angeles native Christina Shaw had two powerful goals when she decided to move cross country to live in Nashville – the first was to support her favorite hockey team and the second was to meet a renowned lung cancer specialist at Vanderbilt-Ingram Cancer Center.

Vanderbilt’s Robert Coffey Jr., M.D., has received an Outstanding Investigator Award from the National Cancer Institute (NCI) — more than $6.6 million over seven years — to support studies aimed at advancing the diagnosis and treatment of colorectal cancer (CRC), a leading cancer killer.